CorMedix reports Q4 2022 net loss $8.2M; FDA grants Type A meeting for DefenCath resubmission

CorMedix Inc.

Q4 2022 net loss $8.2M ($0.20/shr) vs $7.8M loss in Q4 2021; full-year net loss $29.7M ($0.74/shr).
Cash and short-term investments $58.8M at Dec 31, 2022; $7.2M raised via ATM in Q1 2023.
FDA granted Type A meeting in mid-April to discuss DefenCath NDA resubmission; CMO corrective actions completed.
Agreement with Siegfried AG (Hameln, Germany) as backup CMO for DefenCath manufacturing.
Promoted Erin Mistry to EVP/Chief Commercial Officer and Dr. Tushar Mukherjee to SVP/Head of Technical Operations.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CorMedix Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $8.2 million, or $0.20 per share, compared with a net loss of $7.8 million, or $0.20 per share, in the fourt, EPS $0.20 per share.

Period: the fourth quarter and full year ended December 31, 2022
Net income: net loss of $8.2 million, or $0.20 per share, compared with a net loss of $7.8 million, or $0.20 per share, in the fourt
EPS: $0.20 per share
Result: reported results

Exact text from the filing

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-024301

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.